INS and Hyperinsulinemia: CSII treatment of insulin-resistant individuals with T1D increased insulin-stimulated glucose disposal by 30% during euglycemic-hyperinsulinemia, and reduced HbA1c, self-monitored blood glucose levels, and daily insulin requirements by 23%, 30%, and 20%, respectively, vs multiple daily insulin injections (MDIs).